Knopp Biosciences, LLC

Knopp Neurosciences, Inc.

Biohaven Therapeutics Ltd.

Areteia Therapeutics, Inc.

Michael E Bozik

Thomas Petzinger, Jr

Steven Dworetzky

Gregory Hebrank

Wildon Farwell

Valentin K Gribkoff

George T Topalov

Scott S Harried

David A Mareska

James S Hale

Lynn Resnick

Charles A Flentge

Justin K Belardi

James L Mather

Donald Archibald

Kelly Picchione

Thomas Petzinger

Jr Thomas Petzinger

Valentin Gribkoff

Thomas Petzinger Jr

Provided herein are compounds and pharmaceutical compositions comprising a therapeutically effective amount of such compounds, or pharmaceutically acceptable salts, and a pharmaceutically acceptable excipient, and methods of treating neurodevelopmental diseases or disorders (NDD) and developmental and epileptic encephalopathy (DEE), comprising administering such compounds, or pharmaceutically acceptable salts, and pharmaceutical compositions, to pediatric patients.

Methods of use for KV7 channel activators

Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

KV7 channel activators compositions and methods of use

Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.

Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils

Kv7 channel activators compositions and methods of use

Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole.

Compositions and methods for treating conditions related to increased eosinophils

Disclosed herein are methods of treating conditions, which may be associated with elevated levels of plasma cells and/or B-cells, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.

Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders

A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof comprising administering to said subject an effective amount of (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole or pharmaceutically acceptable salt thereof, wherein said subject is a treatment responder. In certain embodiments, said subject is a subject with definite amyotrophic lateral sclerosis, a subject with amyotrophic lateral sclerosis symptom onset duration of less than about 18 months, a subject with a high level of serum creatinine, a subject with concomitant riluzole administration and combinations thereof.

Compositions and methods for treating amyotrophic lateral sclerosis in responders

Disclosed herein are methods of treating conditions, which may be associated with elevated levels of mast cells, basophils, eosinophils, or a combination thereof, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.

Compositions and methods for treating chronic urticaria

Growing community of inventors

Pittsburgh, PA, United States of America

Michael E Bozik